[Effect of a newly developed platinum compound cis-1, 1-cyclobutane dicarboxylato-(2R)-2-methyl-1,4-butane diamine platinum (II), on human ovarian tumors transplanted into nude mice].

The therapeutic effect of cis-1, 1-cyclobutane dicarboxylato-(2R)-2-methyl-1,4-butane diamine platinum (II) (NK 121) on 3 human yolk sac tumors of the ovary (YST-1, YST-2 and YST-3), which were transplanted into nude mice, was compared with that of cisplatin (CDDP). While tumors YST-2 and YST-3 exhibited a broad comparable sensitivity to CDDP and NK 121, YST-1 was substantially more sensitive to CDDP than NK 121. A significant weight loss was noted in the non-tumor bearing nude mice treated with CDDP, as compared with the loss in both control and NK 121-treated groups. NK 121 showed a good antitumor activity without showing severe toxicities.